These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 9861523

  • 1. Pharmacology of the intravenous platelet receptor glycoprotein IIb-IIIa antagonists.
    Kleiman NS.
    Coron Artery Dis; 1998; 9(9):603-16. PubMed ID: 9861523
    [No Abstract] [Full Text] [Related]

  • 2. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB, Tolleson TR, Huang Y, Larsen RL, Mantell RM, Dillard P, Davidian M, Zhang D, Cantor WJ, Sketch MH, Ohman EM, Zidar JP, Gretler D, DiBattiste PM, Tcheng JE, Califf RM, Harrington RA.
    Circulation; 2002 Sep 17; 106(12):1470-6. PubMed ID: 12234950
    [Abstract] [Full Text] [Related]

  • 3. Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment.
    Tcheng JE.
    Am J Cardiol; 1999 May 06; 83(9A):7E-11E. PubMed ID: 10357575
    [No Abstract] [Full Text] [Related]

  • 4. High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists.
    Kereiakes DJ, Broderick TM, Roth EM, Whang D, Mueller M, Lacock P, Anderson LC, Howard W, Blanck C, Schneider J, Abbottsmith CA.
    J Thromb Thrombolysis; 2000 Feb 06; 9(2):149-55. PubMed ID: 10613996
    [Abstract] [Full Text] [Related]

  • 5. Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.
    Proimos G.
    J Thromb Thrombolysis; 2001 Apr 06; 11(2):99-110. PubMed ID: 11406724
    [Abstract] [Full Text] [Related]

  • 6. Effects Of Glycoprotein IIb/IIIa Antagonists: Anti Platelet Aggregation And Beyond.
    Giordano A, Musumeci G, D'Angelillo A, Rossini R, Zoccai GB, Messina S, Coscioni E, Romano S, Romano MF.
    Curr Drug Metab; 2016 Apr 06; 17(2):194-203. PubMed ID: 26652157
    [Abstract] [Full Text] [Related]

  • 7. Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates.
    Moser M, Bertram U, Peter K, Bode C, Ruef J.
    J Cardiovasc Pharmacol; 2003 Apr 06; 41(4):586-92. PubMed ID: 12658060
    [Abstract] [Full Text] [Related]

  • 8. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
    Marciniak SJ, Jordan RE, Mascelli MA.
    Thromb Haemost; 2001 Mar 06; 85(3):539-43. PubMed ID: 11307828
    [Abstract] [Full Text] [Related]

  • 9. Current issues with glycoprotein IIb-IIIa antagonists.
    Schneider DJ.
    Curr Drug Targets; 2011 Nov 06; 12(12):1813-20. PubMed ID: 21718238
    [Abstract] [Full Text] [Related]

  • 10. IIb's are not IIb's.
    Kereiakes DJ, Runyon JP, Broderick TM, Shimshak TM.
    Am J Cardiol; 2000 Apr 27; 85(8A):23C-31C. PubMed ID: 10793177
    [Abstract] [Full Text] [Related]

  • 11. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation.
    Nannizzi-Alaimo L, Alves VL, Phillips DR.
    Circulation; 2003 Mar 04; 107(8):1123-8. PubMed ID: 12615789
    [Abstract] [Full Text] [Related]

  • 12. Different effects of various anti-GPIIb-IIIa agents on shear-induced platelet activation and expression of procoagulant activity.
    Goto S, Tamura N, Li M, Handa M, Ikeda Y, Handa S, Ruggeri ZM.
    J Thromb Haemost; 2003 Sep 04; 1(9):2022-30. PubMed ID: 12941046
    [Abstract] [Full Text] [Related]

  • 13. Abciximab pharmacodynamics are unaffected by antecedent therapy with other GPIIb/IIIa antagonists in non-human primates.
    Nakada MT, Sassoli PM, Tam SH, Nedelman MA, Jordan RE, Kereiakes DJ.
    J Thromb Thrombolysis; 2002 Aug 04; 14(1):15-24. PubMed ID: 12652146
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: potential contributing mechanism of benefit in acute coronary syndromes.
    Li Y, Spencer FA, Ball S, Becker RC.
    J Thromb Thrombolysis; 2000 Aug 04; 10(1):69-76. PubMed ID: 10947916
    [Abstract] [Full Text] [Related]

  • 15. Abciximab, eptifibatide, and tirofiban: comparison of parenteral glycoprotein IIb/IIIa inhibitors.
    Dunn A.
    Conn Med; 1999 Aug 04; 63(8):483-7. PubMed ID: 10500344
    [No Abstract] [Full Text] [Related]

  • 16. [Pathophysiology of platelet activation and pharmacology of GPIIb/IIIa inhibitors].
    Schrör K.
    Herz; 2001 Apr 04; 26 Suppl 1():30-5. PubMed ID: 11349624
    [Abstract] [Full Text] [Related]

  • 17. Differential inhibitory effects of platelet glycoprotein IIb/IIIa antagonists on aggregation induced by procoagulant agonists.
    Ilveskero S, Lassila R.
    Thromb Res; 2006 Apr 04; 117(3):291-7. PubMed ID: 15878612
    [Abstract] [Full Text] [Related]

  • 18. Glycoprotein IIb/IIIa antagonists.
    Hook KM, Bennett JS.
    Handb Exp Pharmacol; 2012 Apr 04; (210):199-223. PubMed ID: 22918732
    [Abstract] [Full Text] [Related]

  • 19. Combined effects of mild hypothermia and glycoprotein IIb/IIIa antagonists on platelet-platelet and leukocyte-platelet aggregation.
    Frelinger AL, Furman MI, Barnard MR, Krueger LA, Dae MW, Michelson AD.
    Am J Cardiol; 2003 Nov 01; 92(9):1099-101. PubMed ID: 14583364
    [Abstract] [Full Text] [Related]

  • 20. Distinct yet complementary mechanisms of heparin and glycoprotein IIb/IIIa inhibitors on platelet activation and aggregation: implications for restenosis during percutaneous coronary intervention.
    Day JR, Malik IS, Weerasinghe A, Poullis M, Nadra I, Haskard DO, Taylor KM, Landis RC.
    Heart; 2004 Jul 01; 90(7):794-9. PubMed ID: 15201252
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.